Clinical Trials
Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19
Glenmark Pharmaceuticals Ltd. a global research-led pharmaceutical company announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients conducted across seven clinical sites in India. The open-label randomized, multicenter clinical trial, conducted in 150...
Press Releases
DuPont Nutrition & Biosciences Announces Research Collaboration with Rutgers University
DuPont Nutrition & Biosciences (DuPont) announced a research collaboration in microbiome science with the Center for Advanced Biotechnology and Medicine (CABM) at Rutgers University in New Jersey.
The two-year research partnership will focus on improving the benefit/risk ratio of chemotherapy...
Packaging & Labelling
DHL in collaboration with R360 is supporting the Logistics Cluster in monitoring supply chains
Deutsche Post DHL Group (DPDHL) and Resilience360 are providing the Global Logistics Cluster, which is led by the United Nations World Food Programme (WFP), access to Resilience360 (R360). R360 offers a comprehensive suite of supply chain risk management solutions....
Press Releases
Pfizer and BioNTech Announce Agreement with the UK for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2
Pfizer Inc. and BioNTech SE announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the...
Press Releases
Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer Inc. and BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300...
Press Releases
Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine
Bavarian Nordic announced the signing of an agreement with AdaptVac, a joint venture established by ExpreS2ion Biotechnologies and NextGen Vaccines spun out of the University of Copenhagen, to license AdaptVac’s proprietary capsid virus like particle (cVLP) technology for coronaviruses,...
Drug Research
BioInvent’s BI-1206 could improve treatment in several cancers
Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in solid cancers in a KOL event hosted by BioInvent on July...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read